Use of denosumab in recurrent giant cell tumour of bone: Report of two cases
| Autor: | Yuva Chandan Reddy J, Sai Kishore VVCh, Rao AS, Satish Rao I |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Journal of Medical and Scientific Research, Vol 8, Iss 1, Pp 29-34 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2321-1326 2394-112X |
| DOI: | 10.17727/JMSR.2020/8-5 |
| Popis: | Giant cell tumour of bone (GCTB) is a locally aggressive benign bone tumour. Though surgery is the mainstay of treatment, recurrence rate is 8% even after extended curettage. Recurettage does not guarantee no recurrence of the tumour. The RANKL-RANK interaction, which leads to the differentiation and functioning of the osteoclast like giant cells are responsible for the osteolytic activity of tumour. Denosumab a RANK ligand inhibitor can be used in recurrent GCTB. We report two cases, where denosumab was used in recurrent GCTB with encouraging results. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|